Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.
antiphospholipid antibodies
antiphospholipid syndrome
phosphatidylserines
prothrombin
thrombosis
Journal
Journal of thrombosis and haemostasis : JTH
ISSN: 1538-7836
Titre abrégé: J Thromb Haemost
Pays: England
ID NLM: 101170508
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
08
06
2022
received:
01
03
2022
accepted:
14
06
2022
pubmed:
18
6
2022
medline:
17
8
2022
entrez:
17
6
2022
Statut:
ppublish
Résumé
Diagnosis of antiphospholipid syndrome (APS) requires persistent presence of lupus anticoagulant (LAC), anticardiolipin (aCL) IgG/IgM, or anti-β2 glycoprotein I (aβ2GPI) IgG/IgM antibodies. Other antiphospholipid antibodies (aPL) such as antiphosphatidylserine/prothrombin antibodies (aPS/PT) are promising in assessment of thrombotic APS (TAPS). To evaluate the added value of aPS/PT IgG and IgM in TAPS. aPS/PT IgG/IgM, aCL IgG/IgM, aβ2GPI IgG/IgM, and LAC were determined in 757 patients (TAPS and controls). aPS/PT cut-off values were calculated, and aPS/PT titers and positivity were compared between TAPS and controls, type of thrombosis, and antibody profiles. Likelihood ratios (LR), odds ratios (OR), and aPL score were determined. aPS/PT IgG and IgM were associated with TAPS and triple positivity. In-house calculated cut-offs were higher for IgM (43 units), compared to manufacturer's cut-off (30 units). Thresholds of 90 (IgG) and 200 (IgM) units were determined as high-titer cut-off. Higher aPS/PT titers were observed in triple positive patients and showed higher LR and OR for TAPS. aPS/PT was independently associated with TAPS when adjusted for aCL/aβ2GPI, but not when adjusted for LAC. In isolated LAC positive patients, aPS/PT was positive in 27.1% TAPS patients and in 77.3% patients with autoimmune disease. Diagnostic value of aPL score did not differ with and without including aPS/PT. aPS/PT positivity, especially with high antibody titer, is associated with TAPS diagnosis. Analysis on top of current laboratory criteria is not essential in TAPS diagnosis, but aPS/PT could be useful in patients with thrombosis and a double positive aPL profile (aCL+/aβ2GPI+).
Sections du résumé
BACKGROUND
Diagnosis of antiphospholipid syndrome (APS) requires persistent presence of lupus anticoagulant (LAC), anticardiolipin (aCL) IgG/IgM, or anti-β2 glycoprotein I (aβ2GPI) IgG/IgM antibodies. Other antiphospholipid antibodies (aPL) such as antiphosphatidylserine/prothrombin antibodies (aPS/PT) are promising in assessment of thrombotic APS (TAPS).
AIM
To evaluate the added value of aPS/PT IgG and IgM in TAPS.
MATERIAL AND METHODS
aPS/PT IgG/IgM, aCL IgG/IgM, aβ2GPI IgG/IgM, and LAC were determined in 757 patients (TAPS and controls). aPS/PT cut-off values were calculated, and aPS/PT titers and positivity were compared between TAPS and controls, type of thrombosis, and antibody profiles. Likelihood ratios (LR), odds ratios (OR), and aPL score were determined.
RESULTS
aPS/PT IgG and IgM were associated with TAPS and triple positivity. In-house calculated cut-offs were higher for IgM (43 units), compared to manufacturer's cut-off (30 units). Thresholds of 90 (IgG) and 200 (IgM) units were determined as high-titer cut-off. Higher aPS/PT titers were observed in triple positive patients and showed higher LR and OR for TAPS. aPS/PT was independently associated with TAPS when adjusted for aCL/aβ2GPI, but not when adjusted for LAC. In isolated LAC positive patients, aPS/PT was positive in 27.1% TAPS patients and in 77.3% patients with autoimmune disease. Diagnostic value of aPL score did not differ with and without including aPS/PT.
CONCLUSION
aPS/PT positivity, especially with high antibody titer, is associated with TAPS diagnosis. Analysis on top of current laboratory criteria is not essential in TAPS diagnosis, but aPS/PT could be useful in patients with thrombosis and a double positive aPL profile (aCL+/aβ2GPI+).
Identifiants
pubmed: 35713971
doi: 10.1111/jth.15785
pii: S1538-7836(22)02100-6
doi:
Substances chimiques
Antibodies, Antiphospholipid
0
Immunoglobulin G
0
Immunoglobulin M
0
Lupus Coagulation Inhibitor
0
Phosphatidylserines
0
beta 2-Glycoprotein I
0
Prothrombin
9001-26-7
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2136-2150Informations de copyright
© 2022 International Society on Thrombosis and Haemostasis.
Références
Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306. doi:10.1111/j.1538-7836.2006.01753.x
Devreese KMJ, Ortel TL, Pengo V, de Laat B. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost. 2018;16:809-813. doi:10.1111/jth.13976
Schreiber K, Sciascia S, de Groot PG, et al. Antiphospholipid syndrome. Nat Rev Dis Prim. 2018;4:17103. doi:10.1038/nrdp.2017.103
Devreese KMJ, de Groot PG, de Laat B, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost. 2020;18:2828-2839. doi:10.1111/jth.15047
Tripodi A. Diagnostic challenges on the laboratory detection of lupus anticoagulant. Biomedicine. 2021;9:844. doi:10.3390/biomedicines9070844
Devreese KMJ. Testing for antiphospholipid antibodies: advances and best practices. Int J Lab Hematol. 2020;42(Suppl 1):49-58. doi:10.1111/ijlh.13195
Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL. Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost. 2014;12:792-795. doi:10.1111/jth.12537
Chayoua W, Kelchtermans H, Moore GW, et al. Detection of anti-cardiolipin and anti-beta2glycoprotein I antibodies differs between platforms without influence on association with clinical symptoms. Thromb Haemost. 2019;119:797-806. doi:10.1055/s-0039-1679901
Van Hoecke F, Persijn L, Decavele AS, Devreese K. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34:630-640. doi:10.1111/j.1751-553X.2012.01448.x
Wienholt LA, Richardson A, Wong RC, Chapman K, Lee FJ. A review of 10 years of data from an external quality assurance program for antiphospholipid antibodies: no evidence for improved aCL and β2GPI assay standardization. Annals of Blood. 2019;4:1-6. doi:10.21037/aob.2019.10.01
Meroni PL, Borghi MO. Antiphospholipid antibody assays in 2021: looking for a predictive value in addition to a diagnostic one. Front Immunol. 2021;12:726820. doi:10.3389/fimmu.2021.726820
Bradacova P, Slavik L, Ulehlova J, et al. Current promising biomarkers and methods in the diagnostics of antiphospholipid syndrome: a review. Biomedicine. 2021;9:166. doi:10.3390/biomedicines9020166
Barbhaiya M, Zuily S, Ahmadzadeh Y, et al. Development of a new international antiphospholipid syndrome classification criteria phase I/II report: generation and reduction of candidate criteria. Arthritis Care Res. 2021;73:1490-1501. doi:10.1002/acr.24520
Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000;43:1982-1993. doi:10.1002/1529-0131(200009)43:9<1982::AID-ANR9>3.0.CO;2-2
Amengual O, Forastiero R, Sugiura-Ogasawara M, et al. Evaluation of phosphatidylserine-dependent antiprothrombin antibody testing for the diagnosis of antiphospholipid syndrome: results of an international multicentre study. Lupus. 2017;26:266-276. doi:10.1177/0961203316660203
Radin M, Foddai SG, Cecchi I, et al. Antiphosphatidylserine/prothrombin antibodies: an update on their association with clinical manifestations of antiphospholipid syndrome. Thromb Haemost. 2020;120:592-598. doi:10.1055/s-0040-1705115
Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014;111:354-364. doi:10.1160/TH13-06-0509
Litvinova E, Darnige L, Kirilovsky A, Burnel Y, de Luna G, Dragon-Durey MA. Prevalence and significance of non-conventional antiphospholipid antibodies in patients with clinical APS criteria. Front Immunol. 2018;9:2971. doi:10.3389/fimmu.2018.02971
Zuily S, de Laat B, Guillemin F, et al. Anti-domain I beta2-glycoprotein I antibodies and activated protein C resistance predict thrombosis in antiphospholipid syndrome: TAC(I)T study. J Appl Lab Med. 2020;5:1242-1252. doi:10.1093/jalm/jfaa072
Cattini MG, Bison E, Pontara E, Cheng C, Denas G, Pengo V. Tetra positive thrombotic antiphospholipid syndrome: major contribution of anti-phosphatidyl-serine/prothrombin antibodies to lupus anticoagulant activity. J Thromb Haemost. 2020;18:1124-1132. doi:10.1111/jth.14765
Pengo V, Del Ross T, Ruffatti A, et al. Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns. Thromb Res. 2018;172:172-178. doi:10.1016/j.thromres.2018.11.003
Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on lupus anticoagulant/antiphospholipid antibody of the scientific and standardisation committee of the international society on thrombosis and haemostasis. J Thromb Haemost. 2009;7:1737-1740. doi:10.1111/j.1538-7836.2009.03555.x
Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem. 1971;17:275-284.
Clinical and Laboratory Standards Institute (CLSI). EP28-A3C: Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory. 2010.
Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504-512. doi:10.1002/art.33340
Chayoua W, Kelchtermans H, Moore GW, et al. Identification of high thrombotic risk triple-positive antiphospholipid syndrome patients is dependent on anti-cardiolipin and anti-beta2glycoprotein I antibody detection assays. J Thromb Haemost. 2018;16:2016-2023. doi:10.1111/jth.14261
Bossuyt X. Clinical performance characteristics of a laboratory test. A practical approach in the autoimmune laboratory. Autoimmun Rev. 2009;8:543-548. doi:10.1016/j.autrev.2009.01.013
Deeks JJ, Altman DG. Diagnostic tests 4: likelihood ratios. BMJ (Clinical Research Ed). 2004;329:168-169. doi:10.1136/bmj.329.7458.168
Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118:1340-1347. doi:10.1161/CIRCRESAHA.115.306841
Manukyan D, Rossmann H, Schulz A, et al. Distribution of antiphospholipid antibodies in a large population-based German cohort. Clin Chem Lab Med. 2016;54:1663-1670. doi:10.1515/cclm-2016-0014
Favaloro EJ, Wheatland L, Jovanovich S, Roberts-Thomson P, Wong RC. Internal quality control and external quality assurance in testing for antiphospholipid antibodies: part I--Anticardiolipin and anti-beta2-glycoprotein I antibodies. Semin Thromb Hemost. 2012;38:390-403. doi:10.1055/s-0032-1311990
Willis R, Lakos G, Harris EN. Standardization of antiphospholipid antibody testing--historical perspectives and ongoing initiatives. Semin Thromb Hemost. 2014;40:172-177. doi:10.1055/s-0033-1364207
Pignatelli P, Ettorre E, Menichelli D, Pani A, Violi F, Pastori D. Seronegative antiphospholipid syndrome: refining the value of “non-criteria” antibodies for diagnosis and clinical management. Haematologica. 2020;105:562-572. doi:10.3324/haematol.2019.221945
Hoxha A, Ruffatti A, Mattia E, et al. Relationship between antiphosphatidylserine/prothrombin and conventional antiphospholipid antibodies in primary antiphospholipid syndrome. Clin Chem Lab Med. 2015;53:1265-1270. doi:10.1515/cclm-2014-1129
Mullen MT, Messe SR, Kasner SE, et al. Anti-phosphatidylserine-prothrombin antibodies are associated with outcome in a TIA cohort. Front Neurol. 2012;3:137. doi:10.3389/fneur.2012.00137
Nunez-Alvarez CA, Hernandez-Molina G, Bermudez-Bermejo P, et al. Prevalence and associations of anti-phosphatidylserine/prothrombin antibodies with clinical phenotypes in patients with primary antiphospholipid syndrome: aPS/PT antibodies in primary antiphospholipid syndrome. Thromb Res. 2019;174:141-147. doi:10.1016/j.thromres.2018.12.023
Shi H, Zheng H, Yin YF, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential diagnostic markers and risk predictors of venous thrombosis and obstetric complications in antiphospholipid syndrome. Clin Chem Lab Med. 2018;56:614-624. doi:10.1515/cclm-2017-0502
Zhang S, Wu Z, Zhang W, et al. Antibodies to phosphatidylserine/prothrombin (aPS/PT) enhanced the diagnostic performance in Chinese patients with antiphospholipid syndrome. Clin Chem Lab Med. 2018;56:939-946. doi:10.1515/cclm-2017-0811
Liu T, Gu J, Wan L, et al. “Nson-criteria” antiphospholipid antibodies add value to antiphospholipid syndrome diagnoses in a large Chinese cohort. Arthritis Res Ther. 2020;22:33. doi:10.1186/s13075-020-2131-4
Egri N, Bentow C, Rubio L, et al. Anti-phosphatidylserine/prothrombin antibodies at two points: correlation with lupus anticoagulant and thrombotic risk. Front Immunol. 2021;12:754469. doi:10.3389/fimmu.2021.754469
Zhu L, Li C, Liu N, et al. Diagnostic value of antibodies to phosphatidylserine/prothrombin complex for antiphospholipid syndrome in Chinese patients. Clin Rheumatol. 2017;36:401-406. doi:10.1007/s10067-016-3498-0
Zuily S, de Laat B, Mohamed S, et al. Validity of the global anti-phospholipid syndrome score to predict thrombosis: a prospective multicentre cohort study. Rheumatology (Oxford). 2015;54:2071-2075. doi:10.1093/rheumatology/kev238
Hoxha A, Mattia E, Tonello M, Grava C, Pengo V, Ruffatti A. Antiphosphatidylserine/prothrombin antibodies as biomarkers to identify severe primary antiphospholipid syndrome. Clin Chem Lab Med. 2017;55:890-898. doi:10.1515/cclm-2016-0638
Kim H, Kim JE, Hwang SM, Lee HR, Han KS, Kim HK. Synergistic thrombotic risk of antibodies against phosphatidylserine and prothrombin and beta-2-glycoprotein I. Clin Appl Thromb Hemost. 2014;20:442-447. doi:10.1177/1076029613497424
Sciascia S, Sanna G, Murru V, Khamashta MA, Bertolaccini ML. Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients. Thromb Res. 2014;133:451-454. doi:10.1016/j.thromres.2013.12.001
Lee JS, Gu J, Park HS, Yoo HJ, Kim HK. Coexistence of anti-beta2-glycoprotein I domain I and anti-phosphatidylserine/prothrombin antibodies suggests strong thrombotic risk. Clin Chem Lab Med. 2017;55:882-889. doi:10.1515/cclm-2016-0676
Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum. 2009;61:29-36. doi:10.1002/art.24232
Vlagea A, Gil A, Cuesta MV, et al. Antiphosphatidylserine/prothrombin antibodies (aPS/PT) as potential markers of antiphospholipid syndrome. Clin Appl Thromb Hemost. 2013;19:289-296. doi:10.1177/1076029612437578
Elbagir S, Grosso G, Mohammed NA, et al. Associations with thrombosis are stronger for antiphosphatidylserine/prothrombin antibodies than for the Sydney criteria antiphospholipid antibody tests in SLE. Lupus. 2021;30:1289-1299. doi:10.1177/09612033211014570
Nojima J, Iwatani Y, Suehisa E, Kuratsune H, Kanakura Y. The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus. Haematologica. 2006;91:699-702.
Tonello M, Bison E, Cattini MG, et al. Anti-phosphatidyl-serine/prothrombin antibodies (aPS/PT) in isolated lupus anticoagulant (LA): is their presence linked to dual test positivity? Clin Chem Lab Med. 2021;59:1950-1953. doi:10.1515/cclm-2021-0692
Pengo V. Additional laboratory tests to improve on the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2020;18:1846-1848. doi:10.1111/jth.14896
Chinnaraj M, Pengo V, Pozzi N. A novel ELISA assay for the detection of anti-prothrombin antibodies in antiphospholipid syndrome patients at high risk of thrombosis. Front Immunol. 2021;12:741589. doi:10.3389/fimmu.2021.741589
Tektonidou MG, Andreoli L, Limper M, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78:1296-1304. doi:10.1136/annrheumdis-2019-215213
Garcia D, Erkan D. Diagnosis and management of the antiphospholipid syndrome. N Engl J Med. 2018;378:2010-2021. doi:10.1056/NEJMra1705454
Unlu O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3:75-84. doi:10.5152/eurjrheum.2015.0085
Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood. 2003;101:1827-1832. doi:10.1182/blood-2002-02-0441
Demir S, Li J, Magder LS, Petri M. Antiphospholipid patterns predict risk of thrombosis in systemic lupus erythematosus. Rheumatology (Oxford). 2021;60:3770-3777. doi:10.1093/rheumatology/keaa857
Garcia D, Akl EA, Carr R, Kearon C. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood. 2013;122:817-824. doi:10.1182/blood-2013-04-496257
Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8:237-242. doi:10.1111/j.1538-7836.2009.03674.x
Mustonen P, Lehtonen KV, Javela K, Puurunen M. Persistent antiphospholipid antibody (aPL) in asymptomatic carriers as a risk factor for future thrombotic events: a nationwide prospective study. Lupus. 2014;23:1468-1476. doi:10.1177/0961203314545410
Yelnik CM, Urbanski G, Drumez E, et al. Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus. 2017;26:163-169. doi:10.1177/0961203316657433
Calcaterra I, Ambrosino P, Vitelli N, et al. Risk assessment and antithrombotic strategies in antiphospholipid antibody carriers. Biomedicine. 2021;9:122. doi:10.3390/biomedicines9020122
Vandevelde A, Chayoua W, de Laat B, et al. Semiquantitative interpretation of anticardiolipin and antibeta2glycoprotein I antibodies measured with various analytical platforms: communication from the ISTH SSC subcommittee on lupus anticoagulant/antiphospholipid antibodies. J Thromb Haemost. 2022;20:508-524. doi:10.1111/jth.15585
Bossuyt X, Rasmussen N, van Paassen P, et al. A multicentre study to improve clinical interpretation of proteinase-3 and myeloperoxidase anti-neutrophil cytoplasmic antibodies. Rheumatology (Oxford). 2017;56:1533-1541. doi:10.1093/rheumatology/kex170
Escalante A, Brey RL, Mitchell BD Jr, Dreiner U. Accuracy of anticardiolipin antibodies in identifying a history of thrombosis among patients with systemic lupus erythematosus. Am J Med. 1995;98:559-565. doi:10.1016/s0002-9343(99)80014-x
Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2013;72:142-143. doi:10.1136/annrheumdis-2012-201985
Sciascia S, Radin M, Sanna G, Cecchi I, Roccatello D, Bertolaccini ML. Clinical utility of the global anti-phospholipid syndrome score for risk stratification: a pooled analysis. Rheumatology (Oxford). 2018;57:661-665. doi:10.1093/rheumatology/kex466
Yin D, de Groot PG, Ninivaggi M, Devreese KMJ, de Laat B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome. Thromb Haemost. 2021;121:1220-1227. doi:10.1055/a-1344-4271